Galeazzi R L, Benet L Z, Sheiner L B
Clin Pharmacol Ther. 1976 Sep;20(3):278-89. doi: 10.1002/cpt1976203278.
The kinetics of a measure of pharmcologic effect (prolongation of the QT interval) of procainamide, as well as the kinetics of the plasma concentration, urine excretion, and saliva concentration of the drug were investigated in 14 trials in 4 subjects. A single 500-mg dose was given by rapid intravenous infusion, and frequent subsequent determinations of the above variables were made. A 2-compartment pharmacokinetic model with a third compartment for the saliva was used to fit the plasma, urine, and saliva data simultaneously. Analysis of the data reveals that the kinetics of the drug concentrations in saliva and of the pharmacologic effect are indistinguishable. They both must be considered to be different from those of the drug concentrations in plasma. Thus, in normal individuals under the conditions of this study, saliva concentrations more precisely indicate the time-course of drug at a cardiac site of action, although they do not parallel plasma drug concentrations until 6 hr or more after a rapid intravenous infusion. The following average pharmacokinetic parameters for plasma were found: terminal half-life, 2.9 hr; total clearance, 828 ml/min; renal clearance, 334 ml/min; and steady-state volume of distribution, 180 L. Average distribution pseudoequilbrium half-time (t1/2 alpha) was 5.2 min from an initial volume of distribution of 36.6 L.
在4名受试者身上进行了14次试验,研究了普鲁卡因胺的一种药理效应指标(QT间期延长)的动力学,以及该药物的血浆浓度、尿排泄和唾液浓度的动力学。通过快速静脉输注给予单次500毫克剂量,并随后频繁测定上述变量。采用一个具有唾液第三房室的二房室药代动力学模型同时拟合血浆、尿液和唾液数据。数据分析表明,唾液中药物浓度的动力学和药理效应是无法区分的。它们都必须被认为与血浆中药物浓度的动力学不同。因此,在本研究条件下的正常个体中,唾液浓度更准确地表明了药物在心脏作用部位的时间进程,尽管在快速静脉输注后6小时或更长时间内,它们与血浆药物浓度并不平行。发现血浆的以下平均药代动力学参数:终末半衰期为2.9小时;总清除率为828毫升/分钟;肾清除率为334毫升/分钟;稳态分布容积为180升。平均分布假平衡半衰期(t1/2α)为5.2分钟,初始分布容积为36.6升。